{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T08:19:40Z","timestamp":1648887580158},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,11,6]],"date-time":"2008-11-06T00:00:00Z","timestamp":1225929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00108-008-2156-2","type":"journal-article","created":{"date-parts":[[2008,11,4]],"date-time":"2008-11-04T10:02:42Z","timestamp":1225792962000},"page":"1452-1457","source":"Crossref","is-referenced-by-count":1,"title":["Chronische myeloproliferative Erkrankungen"],"prefix":"10.1007","volume":"49","author":[{"given":"S.W.","family":"Krause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,6]]},"reference":[{"key":"2156_CR1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809\u20131820","journal-title":"Blood"},{"key":"2156_CR2","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"De","year":"2008","unstructured":"De Lavallade H, Apperley JF, Khorashad JS et al. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26: 3358\u20133363","journal-title":"J Clin Oncol"},{"key":"2156_CR3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"Deininger","year":"2003","unstructured":"Deininger MW, O\u2019Brien SG, Ford JM et al. (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637\u20131647","journal-title":"J Clin Oncol"},{"key":"2156_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"Di","year":"2007","unstructured":"Di Nisio M, Barbui T, Di Gennaro L et al. (2007) The haematocrit and platelet target in polycythemia vera. Br J Haematol 136: 249\u2013259","journal-title":"Br J Haematol"},{"key":"2156_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408\u20132417","journal-title":"N Engl J Med"},{"key":"2156_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G et al. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33\u201345","journal-title":"N Engl J Med"},{"key":"2156_CR7","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M et al. (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686\u20134692","journal-title":"Blood"},{"key":"2156_CR8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","volume":"13","author":"Kerbauy","year":"2007","unstructured":"Kerbauy DM, Gooley TA, Sale GE et al. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13: 355\u2013365","journal-title":"Biol Blood Marrow Transplant"},{"key":"2156_CR9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J et al. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114\u2013124","journal-title":"N Engl J Med"},{"key":"2156_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","volume":"59","author":"Morgan","year":"2008","unstructured":"Morgan KJ, Gilliland DG (2008) A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 59: 213\u2013222","journal-title":"Annu Rev Med"},{"key":"2156_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14\u201322","journal-title":"Leukemia"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2156-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:09Z","timestamp":1558584729000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2156-2"}},"subtitle":["Aktuelle Therapiestandards und neue Entwicklungen"],"short-title":[],"issued":{"date-parts":[[2008,11,6]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["2156"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2156-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,6]]}}}